PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
Immatics N.V. - Ordinary Shares (IMTX)
Company Research
Source: GlobeNewswire
Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered with a PRAME-directed TCR provided by Immatics 17-year-old adolescent with bulky, rapidly progressing nephroblastoma and no remaining treatment options achieved deep remission, including marked regression of liver, lung and brain metastases; response ongoing at 6 months of follow-up PRAME is a multi-pediatric cancer target, and findings highlight the therapeutic potential of PRAME TCR T-cell therapy in pediatric patients with solid tumorsData will be presented in a late-breaking poster at the AACR Annual Meeting 2026 by Dr. med. Christian M. Seitz, Group Leader at KiTZ Houston, Texas and Tuebingen, Germany, April 17, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today
Show less
Read more
Impact Snapshot
Event Time:
IMTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMTX alerts
High impacting Immatics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
IMTX
News
- Immatics (IMTX) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.MarketBeat
- Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside [Yahoo! Finance]Yahoo! Finance
- Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate [Yahoo! Finance]Yahoo! Finance
- Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot [Seeking Alpha]Seeking Alpha
- Immatics (IMTX) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "hold"MarketBeat
IMTX
Earnings
- 11/17/25 - Beat
IMTX
Sec Filings
- 4/17/26 - Form 6-K
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- IMTX's page on the SEC website